WallStreetZenWallStreetZen

NASDAQ: CNTX
Context Therapeutics Inc Stock Ownership - Who owns Context Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Context Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Martin A. LehrChief Executive Officer2025-06-09100,000$0.70
$70.10kBuy
Alex C. LevitChief Legal Officer Corp. Sec2025-06-0620,000$0.58
$11.52kBuy
Jennifer Lynn MinaiazaryChief Financial Officer2025-06-0640,010$0.64
$25.49kBuy

1 of 1

CNTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CNTX insiders and whales buy or sell their stock.

CNTX Shareholders

What type of owners hold Context Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blue Owl Capital Holdings LP8.09%7,432,906$17.10MInstitution
Deep Track Capital LP8.08%7,419,355$17.06MInstitution
Avidity Partners Management LP5.99%5,504,855$12.66MInstitution
Franklin Resources Inc4.36%4,003,380$9.21MInstitution
Vanguard Group Inc4.12%3,785,909$8.71MInstitution
Marshall Wace LLP2.82%2,593,198$5.96MInstitution
Alyeska Investment Group LP1.81%1,663,355$3.83MInstitution
Martin A. Lehr1.18%1,079,891$2.48MInsider
Blackrock Inc0.92%848,046$1.95MInstitution
Geode Capital Management LLC0.66%608,462$1.40MInstitution

1 of 3

CNTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CNTX38.40%1.43%Net Buying
HUMA21.97%16.42%Net Selling
ALEC31.67%43.41%Net SellingNet Selling
OBIO11.16%63.60%Net BuyingNet Selling
SRZN17.37%82.63%Net BuyingNet Buying
View Top Biotech Stocks

Context Therapeutics Stock Ownership FAQ

Who owns Context Therapeutics?

Context Therapeutics (NASDAQ: CNTX) is owned by 38.40% institutional shareholders, 1.43% Context Therapeutics insiders, and 60.17% retail investors. Martin A. Lehr is the largest individual Context Therapeutics shareholder, owning 1.08M shares representing 1.18% of the company. Martin A. Lehr's Context Therapeutics shares are currently valued at $2.52M.

If you're new to stock investing, here's how to buy Context Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.